SEC Form 4/A · accession 0001193805-17-003506
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Period of report
Nov 9, 2017
Accepted (ET)
Nov 16, 2017 · 9:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 9, 2017 | P | 5,813,954 | $2.15 | A | 10,109,534 | I | By Biotest Pharmaceuticals Corporation |
| Non-Voting Common StockF2 | holding | — | — | — | 8,591,160 | I | By Biotest Pharmaceuticals Corporation |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a purchase from the underwriters in the issuer's public offering.
- F2The shares are owned directly by Biotest Pharmaceuticals Corporation, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Biotest AG is a director and a ten percent owner of the issuer.